Trial retention and outcome-data completeness now need a dedicated HTA governance plan
A 20 April 2026 BMJ Open synthesis of participant reasons for trial non-completion turns retention into a concrete evidence-design problem for health technology assessment. When outcome data go missing, comparative estimates, utility inputs, and reimbursement models all become harder to defend.
HTA evidence teams are hitting a fragmentation wall: ITC, MAIC, NMA, RWE, modelling, and reporting now need one traceable workflow, not stitched-together handoffs.
https://www.mattheneus.com/editorial/abangelabs-hta-studio-itc-foundation-end-to-end-hta-evidence-platform-2026-04-02 #HTA #NMA #MAIC #EvidenceSynthesis #HealthEconomics
AbangeLabs HTA Studio: From ITC Foundation to End-to-End HTA Evidence Platform
Health technology assessment (HTA) evidence teams are increasingly asked to deliver multi-method evidence packages spanning indirect treatment comparison (ITC), matching-adjusted indirect comparison (MAIC), network meta-analysis (NMA), economic modelling, and reporting. This article examines why fragmented execution is becoming a methodological governance risk and how AbangeLabs HTA Studio addresses that problem through documented current capabilities.
Germany opens reimbursable Long/Post-COVID off-label use for four medicines
Germany's Federal Joint Committee has moved four Long/Post-COVID off-label recommendations into reimbursable care. The evidence basis is uneven across the package: metformin is anchored in the COVID-OUT randomised controlled trial, while ivabradine, vortioxetine and agomelatine rely on smaller symptom-specific studies with important transferability and bias questions.
German Federal Joint Committee (G-BA) says concizumab added benefit is not proven in haemophilia A
On 19 March 2026, the German Federal Joint Committee (G-BA) concluded that concizumab added benefit is not proven for routine prophylaxis of bleeding in people aged 12 years and older with severe haemophilia A and no factor VIII inhibitors. The core issue was evidence architecture, not a failed positive trial: the submitted package did not provide a relevant comparison against factor VIII prophylaxis or emicizumab, and no accepted indirect treatment comparison supported the claim.
NICE’s fezolinetant decision is a live case study in how reimbursement can clear despite uncertain indirect evidence beyond placebo. The real lesson is comparator-bridge discipline, not false certainty.
https://www.mattheneus.com/editorial/nice-fezolinetant-menopause-final-guidance-indirect-comparison-uncertainty-2026-04-02 #HTA #NMA #MAIC #EvidenceSynthesis #RegulatoryAffairs
National Institute for Health and Care Excellence (NICE) clears fezolinetant when hormone replacement therapy is unsuitable
On 31 March 2026, the National Institute for Health and Care Excellence (NICE) published final guidance TA1143 recommending fezolinetant for moderate to severe vasomotor symptoms associated with menopause when hormone replacement therapy is unsuitable.
RWE fails when it is treated as a late appendix instead of submission architecture. Canada and EU HTA now reward early evidence planning and traceable decision logic.
https://www.mattheneus.com/editorial/rwe-submission-architecture-canada-eu-hta-evidence-planning-playbook-2026-04-01 #HTA #RWE #RegulatoryAffairs #EvidenceSynthesis
Real-world evidence (RWE) is now a submission architecture problem for health technology assessment (HTA) teams, not a late appendix
A new Value in Health Regional Issues environmental scan published online on 31 March 2026 found that 25.5% of Canada's Drug Agency reimbursement submissions from 2020 to mid-2024 already included real-world evidence (RWE), yet reviewers repeatedly challenged data quality, generalisability, and the lack of Canadian data.
AI can already speed up evidence screening and extraction, but the latest validation signal says HTA teams should keep human oversight on judgment-heavy risk-of-bias work.
https://www.mattheneus.com/editorial/ai-evidence-synthesis-validation-coverage-gap-playbook-2026-04-01 #HTA #EvidenceSynthesis #Pharma
Where AI evidence-synthesis validation is strongest, and where HTA teams still need tighter controls
A March 2026 scoping review and validation study show a tighter rule for HTA teams: screening and extraction automation have broader support, but judgement-heavy tasks such as risk-of-bias assessment still require human oversight, validation, and audit-ready lineage.
When two NMAs disagree, the ranking usually isn’t the truth—it’s the output of study selection, population splits, and consistency choices. This playbook shows how to stress-test the decision question before a league table enters a dossier.
https://www.mattheneus.com/editorial/when-two-nmas-disagree-similarity-consistency-governance-playbook-2026-04-01 #HTA #NMA #EvidenceSynthesis #RegulatoryAffairs
When two network meta-analyses disagree: a playbook for similarity, consistency, and ranking discipline
A new commentary in the Journal of the European Academy of Dermatology and Venereology uses two recent hidradenitis suppurativa network meta-analyses as a warning against overinterpreting treatment rankings. For HTA, market access, and evidence teams, the operational lesson is clear: lock the decision question first, document similarity and inconsistency checks explicitly, and show how network design choices change the answer before a ranking enters a dossier.
AMNOG Evidence Architecture for Haemophilia: Designing Split-Population Dossiers for Inhibitor and Non-Inhibitor Subgroups
The G-BA concluded its §35a benefit assessments for concizumab (Alhemo) across three separate procedures in March 2026, covering haemophilia A with inhibitors, haemophilia A without inhibitors, and haemophilia B without inhibitors as distinct AMNOG procedures. This structural feature of German benefit assessment — separate dossiers per patient subgroup — creates a specific and often underestimated evidence-architecture challenge for evidence teams working on novel non-factor haemostatic agents.
G-BA finds no added benefit for ixekizumab in paediatric enthesitis-associated arthritis after comparator-relevance review
On 19 March 2026, G-BA concluded that added benefit is not proven for ixekizumab in paediatric enthesitis-associated arthritis after reviewing comparator relevance and the available evidence package.
AbangeLabs